We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Home » BIOCRYST PHARMACEUTICALS ENTER AGREEMENT WITH GREEN CROSS TO DEVELOP AND COMMERICALIZE PERAMIVIR
BIOCRYST PHARMACEUTICALS ENTER AGREEMENT WITH GREEN CROSS TO DEVELOP AND COMMERICALIZE PERAMIVIR
June 14, 2006
BioCryst Pharmaceuticals (Nasdaq: BCRX) announced an agreement with Green Cross
Corporation, South Korea for the development and commercialization in Korea
of peramivir, BioCryst's potent influenza neuraminidase inhibitor.
